黑色素瘤优先表达抗原（PRAME）在未受累的背景睾丸、原位生殖细胞肿瘤及睾丸生殖细胞肿瘤中的免疫组化表达
Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis.
作者信息
Ricci Costantino, Franceschini Tania, Giunchi Francesca, Grillini Marco, Ambrosi Francesca, Massari Francesco, Mollica Veronica, Colecchia Maurizio, Fiorentino Michelangelo
机构信息
Department of Pathology, Maggiore Hospital, AUSL-Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
出版信息
Am J Clin Pathol. 2022 May 4;157(5):644-648. doi: 10.1093/ajcp/aqab200.
OBJECTIVES
Preferentially expressed antigen in melanoma (PRAME) has a key role in regulating pluripotency of primordial germ cells and in the development of germ cell tumors of the testis (GCTT). However, its immunohistochemical expression in normal testes and its neoplastic counterpart remain largely unknown.
METHODS
We retrospectively investigated the expression of PRAME in 26 cases of GCTT, 21 cases of germ cell neoplasia in situ (GCNIS), and 17 cases of uninvolved background testes.
RESULTS
We found that PRAME was expressed more strongly by seminomatous rather than nonseminomatous GCTT (P = .000) and by pure seminoma rather than the seminoma component of seminomatous/nonseminomatous GCTT (P = .025). In addition, GCNIS and uninvolved background testes displayed high levels of PRAME expression.
CONCLUSIONS
PRAME is an additional marker for the differential diagnosis of GCTT and could play a key role in the transition from seminomatous to nonseminomatous GCTT.
目的
黑色素瘤优先表达抗原（PRAME）在调节原始生殖细胞的多能性以及睾丸生殖细胞肿瘤（GCTT）的发生发展中起关键作用。然而，其在正常睾丸及其肿瘤对应物中的免疫组化表达情况仍 largely 未知。
方法
我们回顾性研究了26例GCTT、21例原位生殖细胞肿瘤（GCNIS）以及17例未受累背景睾丸中PRAME的表达情况。
结果
我们发现，PRAME在精原细胞瘤性GCTT中的表达强于非精原细胞瘤性GCTT（P = .000），在纯精原细胞瘤中的表达强于精原细胞瘤性/非精原细胞瘤性GCTT中的精原细胞瘤成分（P = .025）。此外，GCNIS和未受累背景睾丸显示出高水平的PRAME表达。
结论
PRAME是GCTT鉴别诊断的一个额外标志物，并且可能在精原细胞瘤性向非精原细胞瘤性GCTT的转变中起关键作用。
Zotero 插件